{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:24Z","timestamp":1763754864163,"version":"3.45.0"},"reference-count":19,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2010,8,1]]},"DOI":"10.1188\/10.cjon.419-422","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:45:40Z","timestamp":1280882740000},"page":"419-422","source":"Crossref","is-referenced-by-count":0,"title":["A Case Study Progression to Multiple Myeloma"],"prefix":"10.1188","volume":"14","author":[{"given":"Mary Ann","family":"Yancey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Waxman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2010,8,2]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma","volume":"112","author":"B. Barlogie","year":"2008","journal-title":"Blood"},{"key":"2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: Current diagnostic criteria, new predictors of outcome, and follow-up recommendations","volume":"28","author":"J. Blade","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"A. Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2014A randomized study","volume":"50","author":"M. Hjorth","year":"1993","journal-title":"European Journal of Haematology"},{"key":"5","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders. <i>British Journal of Haematology, 121<\/i>, 749-757. doi: 10.1046\/j.1365-2141.2003.04355.x","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"S. Kumar","year":"2008","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"R. Kyle","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"8","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"R. Kyle","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"R. Kyle","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study","volume":"113","author":"O. Landgren","year":"2009","journal-title":"Blood"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9442-2","article-title":"The evolution and impact of therapy in multiple myeloma","volume":"27","author":"J. Laubach","year":"2010","journal-title":"Medical Oncology"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Mateos, M. V., Lopez-Corral, L., Hernandez, M. T., de la Rubia, J., Lahuerta, J. J., Giraldo, P., \u2026 San-Miguel, J. F. (2009). Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM. Retrieved from <a target=\"_blank\" href='http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper21268.html'>http:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper21268.html<\/a>","DOI":"10.1182\/blood.V114.22.614.614"},{"key":"13","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"P. Musto","year":"2008","journal-title":"Cancer"},{"key":"14","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"E. Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"S. Rajkumar","year":"2005","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"21","author":"S. Rajkumar","year":"2007","journal-title":"Blood Reviews"},{"key":"17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1200\/JCO.2009.25.4177","article-title":"Patterns of improved survival in patients with multiple myeloma in the twenty-first century: A population-based study","volume":"28","author":"I. Turesson","year":"2009","journal-title":"Journal of Clinical Oncology"},{"journal-title":"Clinical Lymphoma, Myeloma, and Leukemia","article-title":"Smoldering (asymptomatic) multiple myeloma: Revisiting the clinical dilemma and looking into the future","author":"A. Waxman","key":"18"},{"key":"19","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"B. Weiss","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/KG518831U00L2488.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:16Z","timestamp":1763754556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/14\/4\/case-study-progression-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8,1]]}},"alternative-id":["KG518831U00L2488"],"URL":"https:\/\/doi.org\/10.1188\/10.cjon.419-422","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2010,8,1]]}}}